Discontinuation of oral antivirals in chronic hepatitis B: A systematic review

George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen – 11 January 2016 – The possibility of safe discontinuation of therapy with nucleos(t)ide analogues (NAs) remains one of the most controversial topics in the management of chronic hepatitis B. Therefore, we systematically reviewed the existing data on NA discontinuation in this setting and tried to identify factors affecting the probability of posttherapy remission.

Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha

Seema S. Desai, Jason C. Tung, Vivian X. Zhou, James P. Grenert, Yann Malato, Milad Rezvani, Regina Español‐Suñer, Holger Willenbring, Valerie M. Weaver, Tammy T. Chang – 11 January 2016 – Matrix rigidity has important effects on cell behavior and is increased during liver fibrosis; however, its effect on primary hepatocyte function is unknown. We hypothesized that increased matrix rigidity in fibrotic livers would activate mechanotransduction in hepatocytes and lead to inhibition of liver‐specific functions.

Glial cell line–derived neurotrophic factor–induced mice liver defatting: A novel strategy to enable transplantation of steatotic livers

Sahar Taba Taba Vakili, Roshni Kailar, Khalidur Rahman, Behtash Ghazi Nezami, Simon Musyoka Mwangi, Frank A. Anania, Shanthi Srinivasan – 30 December 2015 – Moderate macrovesicular steatosis (>30%), which is present in almost 50% of livers considered for transplantation, increases the risk of primary graft dysfunction. Our previously published data showed that glial cell line–derived neurotrophic factor (GDNF) is protective against high‐fat diet (HFD)–induced hepatic steatosis in mice.

Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high‐risk liver transplantation recipients: A propensity score analysis

Jesús Fortún, Alfonso Muriel, Pilar Martín‐Dávila, Miguel Montejo, Oscar Len, Julian Torre‐Cisneros, Jordi Carratalá, Patricia Muñoz, Maria Carmen Fariñas, Asunción Moreno, Gema Fresco, Josune Goikoetxea, Joan Gavaldá, Juan Carlos Pozo, Marta Bodro, Antonio Vena, Fernando Casafont, Carlos Cervera, José Tiago Silva, José M.

Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

Yumin Oh, Ogyi Park, Magdalena Swierczewska, James P. Hamilton, Jong‐Sung Park, Tae Hyung Kim, Sung‐Mook Lim, Hana Eom, Dong Gyu Jo, Choong‐Eun Lee, Raouf Kechrid, Panagiotis Mastorakos, Clark Zhang, Sei Kwang Hahn, Ok‐Cheol Jeon, Youngro Byun, Kwangmeyung Kim, Justin Hanes, Kang Choon Lee, Martin G. Pomper, Bin Gao, Seulki Lee – 28 December 2015 – Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration–approved targeted antifibrotic therapy exists.

Subscribe to